Eledon Pharmaceuticals
ELDN
28 hedge funds and large institutions have $12.2M invested in Eledon Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 8 closing their positions.
4% less capital invested
Capital invested by funds: $12.7M → $12.2M (-$491K)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
15% less funds holding
Funds holding: 33 → 28 (-5)
29.45% less ownership
Funds ownership: 67.31% → 37.87% (-29%)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $6K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$117K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$23.2K |
| 3 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$17.4K |
| 4 |
CRC
Curi RMB Capital
Chicago,
Illinois
|
+$13.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$304K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$154K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$30.2K |
| 4 |
JE
JMAC Enterprises
Newtown,
Pennsylvania
|
-$29.4K |
| 5 |
AC
Armistice Capital
New York
|
-$25.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $2.95K | – | – | – |
|
27
Wells Fargo
San Francisco,
California
| $236 | +$35 | +26 | +18% |
|
28
JP Morgan Chase
New York
| $36 | +$35 | +26 | New |
|
|
IC
29
Ikarian Capital
Dallas,
Texas
| – | -$304K | -221,830 | Closed |
|
|
BFM
30
Boothbay Fund Management
New York
| – | -$30.2K | -22,050 | Closed |
|
|
VF
31
Virtu Financial
New York
| – | -$24K | -17,675 | Closed |
|
32
Jane Street
New York
| – | -$21.6K | -15,783 | Closed |
|
|
V
33
Veritable
Wilmington,
Delaware
| – | -$17.9K | -13,029 | Closed |
|
34
Two Sigma Investments
New York
| – | -$14.5K | -10,586 | Closed |
|
35
Citadel Advisors
Miami,
Florida
| – | -$10.6K | -7,740 | Closed |
|
36
UBS Group
Zurich,
Switzerland
| – | -$44 | -32 | Closed |
|
ELDN Hedge Fund Activity: Q3 2023 in Review
28 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2023, worth a combined $12.2M — down 3.9% from $12.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ELDN and 3 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Woodline Partners, adding an estimated $117K. The largest seller was Ikarian Capital, exiting entirely with an estimated $304K sold.
- 28 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2023, down from 33 in Q2 2023.
- Funds reported $12.2M of Eledon Pharmaceuticals stock for Q3 2023, down 3.9% quarter-over-quarter.
- 3 funds opened new Eledon Pharmaceuticals positions in Q3 2023 and 8 closed out, a net change of -5 holders.
- The largest Eledon Pharmaceuticals buyer in Q3 2023 was Woodline Partners, an estimated $117K added.
- The largest Eledon Pharmaceuticals seller in Q3 2023 was Ikarian Capital, an estimated $304K sold.
Based on aggregated 13F filings for Q3 2023.